Empagliflozin reduces mortality and hospitalisation for heart failure in patients with or without a history of myocardial infarction or stroke at baseline

In the EMPA-REG OUTCOME trial, empagliflozin added to standard of care reduced cardiovascular (CV) death by 38% (HR 0.62 [95% CI 0.49, 0.77]), all-cause mortality by 32% (HR 0.68 [95% CI 0.57, 0.82]) and hospitalisation for heart failure (HHF) by 35% (HR 0.65 [95% CI 0.50, 0.85]) vs. placebo in patients with type 2 diabetes (T2D) and established CV disease. We investigated whether a history of myocardial infarction (MI) or stroke at baseline influenced the effect of empagliflozin on these outcomes.